nor-Binaltorphimine dihydrochloride: A Benchmark κ-Opioid Receptor Antagonist for Signal Transduction Research

Executive Summary: nor-Binaltorphimine dihydrochloride is a potent and selective antagonist of the κ-opioid receptor (KOR), with a molecular weight of 734.72 and formula C₄₀H₄₃N₃O₆·2HCl (APExBIO, B6269). It exhibits <18.37 mg/mL solubility in DMSO and is stored optimally at -20°C, with solutions recommended for prompt use. nor-Binaltorphimine dihydrochloride enables precise interrogation of κ-opioid receptor signaling and is pivotal in pain and addiction research (Huo et al., 2023). Its specificity allows researchers to delineate the physiological and pathological roles of KORs, as demonstrated in mechanistic studies of mechanical allodynia and descending pain modulation circuits. The product is distributed by APExBIO with ≥98% purity and is intended exclusively for research applications.

Biological Rationale

κ-Opioid receptors (KORs) are G protein-coupled receptors that mediate key central and peripheral neurophysiological processes, including pain modulation, mood regulation, and stress response (Huo et al., 2023). KORs are densely expressed in the spinal dorsal horn, hypothalamus, and limbic brain regions. Dysregulation of KOR signaling is implicated in chronic pain, depression, and substance use disorders. Selective antagonists such as nor-Binaltorphimine dihydrochloride provide critical tools for dissecting KOR-mediated signaling pathways, enabling researchers to isolate the contributions of the κ-opioid system from other opioid receptor subtypes (see also—this article extends previous coverage by detailing recent in vivo circuit studies).

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride functions as a highly selective and long-acting antagonist of κ-opioid receptors. It binds to KORs with nanomolar affinity, competitively inhibiting endogenous and exogenous agonists without significantly affecting μ- or δ-opioid receptors (Huo et al., 2023). This selectivity enables targeted disruption of KOR-mediated signal transduction, particularly in studies assessing the role of these receptors in pain transmission and modulation. The compound’s effect is characterized by dose-dependent, reversible inhibition of KOR activity, permitting temporal and spatial precision in experimental designs. Its long duration of action supports sustained receptor blockade in both in vitro and in vivo models.

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride blocks spinal KORs, resulting in long-lasting bilateral mechanical allodynia after nerve injury in murine models (Huo et al., 2023—Figure 5d).
• Inhibition of KOR signaling disrupts the hypothalamic dynorphin/spinal KOR inhibitory circuit, leading to extended pain hypersensitivity duration (Huo et al., 2023—Extended Data).
• Selective KOR antagonism with nor-Binaltorphimine dihydrochloride does not interfere with μ-opioid or δ-opioid receptor function under standard assay conditions (APExBIO product data).
• Compared to earlier antagonists, nor-Binaltorphimine dihydrochloride demonstrates superior selectivity and longer functional blockade, as validated in opioid receptor antagonist assays (Related article; this article extends on pharmacodynamic duration data).
• The product displays robust performance in opioid receptor pharmacology workflows, supporting translational pain and addiction research (Related review; here, new mechanistic insights are highlighted).

Applications, Limits & Misconceptions

Applications

• Dissection of κ-opioid receptor signaling pathways in pain and addiction models.
• Functional studies of descending pain modulation and spinal cord circuitry.
• Pharmacological validation of KOR involvement in mechanical allodynia and stress response.
• Benchmarking in opioid receptor antagonist assays to assess compound selectivity.
• Translational research on chronic pain and substance dependence mechanisms.

For exploration of circuit-level pain modulation, nor-Binaltorphimine dihydrochloride enables precise manipulation, as recently shown in brain-to-spinal pathways research (previous coverage; this article clarifies mechanistic links with new in vivo data).

Common Pitfalls or Misconceptions

• nor-Binaltorphimine dihydrochloride is not selective for μ- or δ-opioid receptors and should not be used to study these systems.
• It is not suitable for diagnostic or therapeutic use; it is intended for research purposes only (APExBIO).
• Long-term storage of solutions leads to degradation; always prepare fresh solutions for each experiment.
• The compound’s in vivo efficacy and duration may vary based on administration route and species; users must validate protocols for their systems.
• It does not reverse established KOR agonist-induced responses instantaneously—functional blockade is sustained and onset may be delayed.

Workflow Integration & Parameters

nor-Binaltorphimine dihydrochloride is supplied as an off-white solid (≥98% purity) by APExBIO (product B6269). The compound has a molecular weight of 734.72 g/mol and a chemical formula of C₄₀H₄₃N₃O₆·2HCl. Solubility in DMSO is less than 18.37 mg/mL; aqueous solubility is limited. Aliquots should be stored at -20°C to maintain stability. For solution-phase experiments, prepare fresh solutions immediately prior to use; avoid repeated freeze-thaw cycles. Shipping is performed on blue ice for small molecules to preserve compound integrity. In receptor binding and antagonist assays, use validated concentrations (typically 1–10 μM in vitro; adjust for animal studies per protocol). Integrate nor-Binaltorphimine dihydrochloride into opioid receptor antagonist assays and signaling studies to dissect KOR-specific pathways, as detailed in recent pain circuit research (related article; this review updates circuit-level applications).

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride remains the gold-standard for selective inhibition of κ-opioid receptor signaling in preclinical research. Its high specificity, validated performance, and robust stability parameters position it as an essential tool for dissecting KOR involvement in pain modulation, addiction, and neurocircuitry studies. Ongoing research is expanding its utility in translational models of chronic pain and neuropsychiatric disorders. For detailed specifications and ordering, refer to the APExBIO product page.